A personal view on antibody drug development
Drug Discovery World
APRIL 14, 2023
Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer.
Let's personalize your content